GlassScriptPhysician profile
Umbreen A Hussain
NPI 1982022364
$8,553.70
in general payments reported to CMS, 2019-2025
30 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $244 · 2021: $650 · 2022: $1,180 · 2023: $2,504 · 2024: $2,172 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,242 · Education: $12.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,242.25 |
| Education | $12.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,555.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $731.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $703.45 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.68 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $553.45 | 2022-2025 | Verquvo, Capvaxive |
| Abbvie INC. | $545.52 | 2021-2025 | |
| Novo Nordisk INC | $508.95 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $496.33 | 2020-2024 | Xarelto |
| United Therapeutics Corporation | $433.63 | 2022-2024 | Tyvaso, Orenitram |
| Pfizer INC. | $420.33 | 2020-2025 | |
| Lilly USA, LLC | $368.45 | 2020-2025 | Zepbound, Mounjaro |
| Scpharmaceuticals INC. | $233.14 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.41 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $195.31 | 2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.90 | 2019-2025 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $171.24 | 2020-2024 | Nexletol |
| Amgen INC. | $131.36 | 2021-2024 | Repatha |
| Medtronic Vascular, INC. | $117.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $95.70 | 2022-2023 | |
| Glaxosmithkline, LLC. | $55.30 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $49.97 | 2024-2025 | Opsumit, Opsynvi |
| Philips North America LLC | $48.82 | 2020-2022 | |
| Genzyme Corporation | $37.22 | 2019-2023 | |
| Portola Pharmaceuticals, LLC | $25.94 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $20.76 | 2023 | Arcalyst |
| Medtronic, INC. | $17.45 | 2023 | Venaseal |
| Allergan, INC. | $15.71 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.02 | 2024 | |
| Abiomed | $12.40 | 2019 | |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umbreen Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.